Early-stage funding for European life sciences companies

We are a venture capital firm specialised in seed investment for innovative early stage companies. BGV generally acts as lead investor. Our current portfolio comprises of biotech developing truly disruptive solutions for high unmet medical needs.

Acerta, a multi-billion Euro success story

BioGeneration was co-founder and investor in the most successful biotech startup in Europe: Acerta Pharma. Acerta Pharma has developed Calquence® (acalabrutinib), a drug now approved by the FDA for the treatment of hematologic malignancies (leukemia). Acerta was sold to AstraZeneca for up to US$ 7 billion in 2016.

Shaping new life-science ventures

We gained our experience from working within small and large pharma and biotech companies. Based on this experience and through our extensive industry network, we are able to bring a range of sector-relevant expertise to help accelerate product development and shape the companies to become attractive investment opportunities for the industry.

Latest news

BGV Expands Team with the Appointment of a Partner and Venture Partner

Sep 14, 2021

Naarden, The Netherlands, 14 September 2021 – BioGeneration Ventures (“BGV”), a leading early-stage VC in European biopharma, today announces the appointment of Keno Gutierrez as Partner, and Wouter Verhoeven as Venture Partner. Collectively these two appointments...

Citryll Announces Dosing of the First Healthy Volunteer in a Phase 1 Clinical Trial for CIT-013, a First in Class Antagonist of NET Biology

Aug 17, 2021

First-in-human study evaluating CIT-013, a humanized monoclonal antibody targeting Neutrophil Extracellular Traps (NETs)CIT-013 binds to citrullinated Histones H2A and H4CIT-013 inhibits NET formation, promotes tissue NET clearance, and hence blocks the...

Kyowa Kirin Taps Synaffix ADC Technology to Expand Its Pipeline

Aug 4, 2021

Synaffix will provide all necessary proprietary ADC technologies, including GlycoConnect™, HydraSpace™, and select toxSYN™ linker-payloads Kyowa Kirin will leverage its innovative antibody-based therapeutics pipeline to develop a portfolio of ADCs with optimized...

Synaffix Announces Deal with ProfoundBio Worth up to $246 Million Providing Access to Multiple Novel Linker-Payload Technologies

Jul 22, 2021

Amsterdam, The Netherlands , July 22, 2021 – Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology that enables antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announced the signature of a...

News overview

Next events

16 – 21 September EMSO Congress 2021

Aug 27, 2021

The ESMO (European Society for Medical Oncology) Congress is the most influential oncology platform designed in Europe for clinicians, researchers, patient advocates, journalists and healthcare industry representatives from all over the world.

19 September Sachs 20th Annual Biotech in Europe Forum

Aug 27, 2021

The 20th Annual Biotech in Europe (BEF) Forum is recognised as the leading international Stage for those interested in investing and partnering in the biotech and life science industry. This highly transactional event draws together an exciting cross-section of...

20 – 22 September Nordic Innovation Fair

Aug 27, 2021

The Nordic Innovation Fair will showcase more than 120 business opportunities, offering a free and unique matchmaking and networking opportunity by bringing together all stakeholders across the innovation ecosystem. Researchers and spinouts from Sweden, Norway,...

Event overview